Control of Trypanosoma cruzi infection and changes in T-cell populations induced by a therapeutic DNA vaccine in mice

Immunology Letters

Volumn 103, Issue 2, 2006, Pages 186-191

  Zapata Estrella, Hiatzy ^a   Hummel Newell, Caroline ^a   Sanchez Burgos, Gilma ^a,b   Escobedo Ortegon, Javier ^a   Ramirez Sierra, Maria Jesus ^a   Arjona Torres, Arletty ^a   Dumonteil, Eric ^a  

^a UNIVERSIDAD AUTÓNOMA DE YUCATÁN   (Mexico)

^b UNIVERSIDAD JUÁREZ AUTÓNOMA DE TABASCO   (Mexico)

Author keywords

Chagas disease; Parasite; Therapeutic vaccine

Indexed keywords

DNA VACCINE; GAMMA INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CHAGAS DISEASE; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; HISTOPATHOLOGY; IMMUNOTHERAPY; INFECTION CONTROL; LYMPHOCYTE SUBPOPULATION; MOUSE; MYOCARDITIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TRYPANOSOMA CRUZI; TRYPOMASTIGOTE;

ACUTE DISEASE; ANIMALS; CHAGAS DISEASE; CHRONIC DISEASE; MICE; MICE, INBRED ICR; T-LYMPHOCYTES; TIME FACTORS; TRYPANOSOMA CRUZI; VACCINES, DNA;

EID: 31544445230     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2005.11.015     Document Type: Article

References (38)

1. E. Dumonteil Update on Chagas' disease in Mexico Salud Publica Mex 41 1999 322 327
2. R.B. Bestetti, and G. Muccillo Clinical course of Chagas' heart disease: a comparison with dilated cardiomyopathy Int J Cardiol 60 1997 187 193
3. D. Steverding, and K.M. Tyler Novel antitrypanosomal agents Expert Opin Invest Drugs 14 2005 939 955
4. L.R. Garzoni, M.C. Waghabi, M.M. Baptista, S.L. de Castro, N. Meirelles Mde, and C.C. Britto Antiparasitic activity of risedronate in a murine model of acute Chagas' disease Int J Antimicrob Agents 23 2004 286 290
5. B. Bouzahzah, L.A. Jelicks, S.A. Morris, L.M. Weiss, and H.B. Tanowitz Risedronate in the treatment of murine Chagas' disease Parasitol Res 96 2005 184 187
6. P.M. Guedes, J.A. Urbina, M. de Lana, L.C. Afonso, V.M. Veloso, and W.L. Tafuri Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts Antimicrob Agents Chemother 48 2004 4286 4292
7. J.A. Urbina Chemotherapy of Chagas disease Curr Pharm Des 8 2002 287 295
8. B. Autran, G. Carcelain, B. Combadiere, and P. Debre Therapeutic vaccines for chronic infections Science 305 2004 205 208
9. D.M. Klinman Immunotherapeutic uses of CpG oligodeoxynucleotides Nat Rev Immunol 4 2004 249 259
10. J. Machado-Pinto, J. Pinto, C.A. da Costa, O. Genaro, M.J. Marques, and F. Modabber Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial Int J Dermatol 41 2002 73 78
11. M. Mancini-Bourgine, H. Fontaine, D. Scott-Algara, S. Pol, C. Brechot, and M.L. Michel Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers Hepatology 40 2004 874 882
12. J. Convit, M. Ulrich, M.A. Polegre, A. Avila, N. Rodriguez, and M.I. Mazzedo Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and bacillus Calmette-Guerin: preliminary report Membr Inst Oswaldo Cruz 99 2004 57 62
13. C. Bahloul, S.B. Ahmed, B.I. B'Chir, H. Kharmachi, A. Hayouni el, and K. Dellagi Post-exposure therapy in mice against experimental rabies: a single injection of DNA vaccine is as effective as five injections of cell culture-derived vaccine Vaccine 22 2003 177 184
14. G.P. Borja-Cabrera, A. Cruz Mendes, E. Paraguai de Souza, L.Y. Hashimoto Okada, A.T.F.A. de, and J.K. Kawasaki Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine Vaccine 22 2004 2234 2243
15. S.J. Ha, B.Y. Jeon, S.C. Kim, D.J. Kim, M.K. Song, and Y.C. Sung Therapeutic effect of DNA vaccines combined with chemotherapy in a latent infection model after aerosol infection of mice with Mycobacterium tuberculosis Gene Ther 10 2003 1592 1599
16. E. Dumonteil, J. Escobedo-Ortegon, N. Reyes-Rodriguez, M.J. Ramirez-Sierra, and A. Arjona-Torres Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice Infect Immun 72 2004 46 53
17. + cells, interferon-gamma recovery and reduction of lung injury Immunology 113 2004 130 138
18. E. Handman, A.H. Noormohammadi, J.M. Curtis, T. Baldwin, and A. Sjolander Therapy of murine cutaneous leishmaniasis by DNA vaccination Vaccine 18 2000 3011 3017
19. + T cell-mediated protective immunity against Trypanosoma cruzi Int Immunol 11 1999 133 141
20. R.L. Tarleton, M.J. Grusby, M. Postan, and L.H. Glimcher Trypanosoma cruzi infection in MHC-deficient mice: further evidence for the role of both class I- and class II-restricted T cells in immune resistance and disease Int Immunol 8 1996 13 22
21. M. Rosado-Vallado, M. Mut-Martin, M.R. Garcia-Miss, and E. Dumonteil Aluminium phosphate potentiates DNA vaccines against Leishmania mexicana Vaccine 23 2005 5372 5379
22. C.R.F. Marinho, M.R. D'Imperio Lima, M.G. Grisotto, and J.M. Alvarez Influence of acute-phase parasite load on pathology, parasitism, and activation of the immune system at the late chronic phase of Chagas' disease Infect Immun 67 1999 308 318
23. M.V. Caliari, R. do Pilar Machado, M. de Lana, R.A. Caja, C.M. Carneiro, and M.T. Bahia Quantitative analysis of cardiac lesions in chronic canine chagasic cardiomyopathy Rev Inst Med Trop Sao Paulo 44 2002 273 278
24. L.J. Roberts, S.J. Foote, and E. Handman A new standard for the assessment of disease progression in murine cutaneous leishmaniasis Parasite Immunol 22 2000 231 237
25. D.F. Hoft, R.G. Lynch, and L.V. Kirchhoff Kinetic analysis of antigen-specific immune responses in resistant and susceptible mice during infection with Trypanosoma cruzi J Immunol 151 1993 7038 7047
26. R.A. Wrightsman, B.D. Dawson, D.L. Fouts, and J.E. Manning Identification of immunodominant epitopes in Trypanosoma cruzi trypomastigote surface antigen-1 protein that mask protective epitopes J Immunol 153 1994 3148 3154
27. + T cells in Trypanosoma cruzi infection Immunol Rev 201 2004 304 317
28. + T cell-mediated immune response during intracellular parasitic infections and its implications for the development of effective vaccines Ann Acad Braz Cienc 75 2003 443 468
29. D.F. Hoft, and Eickhoff CS Type 1 immunity provides optimal protection against both mucosal and systemic Trypanosoma cruzi challenges Infect Immun 70 2002 6715 6725
30. + T-cell epitopes are important for efficient protective immunity induced by DNA vaccination with a Trypanosoma cruzi gene Infect Immun 69 2001 5477 5486
31. B. Wizel, N. Garg, and R.L. Tarleton Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection Infect Immun 66 1998 5073 5081
32. S.A. Laucella, M. Postan, D. Martin, B. Hubby Fralish, M.C. Albareda, and M.G. Alvarez Frequency of interferon-gamma-producing T cells specific for Trypanosoma cruzi inversely correlates with disease severity in chronic human Chagas disease J Infect Dis 189 2004 909 918
33. W.C. Lai, S.P. Pakes, K. Ren, Y.-S. Lu, and M. Bennett Therapeutic effect of DNA immunization of genetically susceptible mice infected with virulent Mycoplasma pulmonis J Immunol 158 1996 2513 2516
34. D.B. Lowrie, R.E. Tascon, Bonato VLD, Lima VMF, L.H. Faccioli, and E. Stravropoulos Therapy of tuberculosis in mice by DNA vaccination Nature 400 1999 269 271
35. R.R. MacGregor, J.D. Boyer, K.E. Ugen, K.E. Lacy, S.J. Gluckman, and M.L. Bagarazzi First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response J Infect Dis 178 1998 92 100
36. R.L. Tarleton Parasite persistence in the aetiology of Chagas disease Int J Parasitol 31 2001 550 554
37. E. Johansson, P. Wallgren, L. Fuxler, K. Domeika, F. Lefevre, and C. Fossum The DNA vaccine vector pcDNA3 induces IFN-alpha production in pigs Vet Immunol Immunopathol 87 2002 29 40
38. T. Verfaillie, E. Cox, and B.M. Goddeeris Immunostimulatory capacity of DNA vaccine vectors in porcine PBMC: a specific role for CpG-motifs? Vet Immunol Immunopathol 103 2005 141 151